Core Viewpoint - The chairman of Wantai Biological Pharmacy (万泰生物), Qiu Zixin, plans to reduce his shareholding through a centralized bidding method, with all proceeds from the sale intended for donation to Xiamen University Education Development Foundation and Xiamen No. 1 Middle School, raising investor interest and media attention [1][4]. Company Overview - Wantai Biological, established in 1991, focuses on the research, production, and sales of diagnostic reagents, vaccines, and medical devices, with its main business divided into in vitro diagnostics and vaccines [1]. - The actual controller of Wantai Biological is Zhong Shanshan, who holds 73.49% of the company's shares [1]. Shareholding Reduction Plan - Qiu Zixin plans to reduce his holdings by up to 5 million shares, representing no more than 0.3954% of the total share capital, between March 12, 2026, and June 11, 2026 [5]. - As of now, Qiu Zixin holds 3.5469% of Wantai Biological's shares [1]. HPV Vaccine Development - Wantai Biological has a strong position in the HPV vaccine sector, having launched the domestically developed bivalent HPV vaccine (Xinkening) in 2019, which was the first of its kind in China, and is expected to launch the nine-valent HPV vaccine (Xinkening 9) in 2025 [1]. Financial Performance and Market Reaction - In 2025, Wantai Biological's stock price fell by 36.22%, and the company is projected to report its first loss since its listing, with an expected net loss of between 330 million to 410 million yuan [6]. - Following the announcement of the share reduction plan, the company's stock price experienced a slight decline over three consecutive days, nearing its October 2023 low, with a closing price of 40.47 yuan and a market capitalization of approximately 51.17 billion yuan [6]. Investor Concerns - Investors have expressed concerns regarding the potential impact of the share reduction on market liquidity, the choice of centralized bidding over block trading, and the complexity of the donation process [7].

Core Viewpoint - The chairman of Wantai Biological Pharmacy, Qiu Zixin, plans to reduce his shareholding through a centralized bidding method, with all proceeds from the sale intended for donation to Xiamen University Education Development Foundation and Xiamen No.1 Middle School [2][5]. Company Overview - Wantai Biological Pharmacy was established in 1991 and focuses on the research, production, and sales of diagnostic reagents, vaccines, and medical devices. The company operates mainly in two sectors: in vitro diagnostics and vaccines [2]. - The actual controller of Wantai Biological is Zhong Shanshan, who holds 73.49% of the company's shares [2]. HPV Vaccine Development - Wantai Biological has a strong presence in the HPV vaccine sector, having launched its self-developed bivalent HPV vaccine (Xinkening) in 2019, which was the first domestically produced bivalent HPV vaccine in China. The nine-valent HPV vaccine (Xinkening 9) is expected to be approved for market release in 2025, marking it as the first domestically produced nine-valent HPV vaccine [2]. Shareholding Reduction Plan - Qiu Zixin announced a plan to reduce his shareholding by up to 5 million shares, which represents no more than 0.3954% of the company's total share capital. The reduction period is set from March 12, 2026, to June 11, 2026 [5]. - As of now, Qiu Zixin holds 3.5469% of Wantai Biological's shares [2]. Financial Performance and Market Reaction - In 2021, Wantai Biological's stock price peaked at 146.54 yuan, with a net profit exceeding 2 billion yuan. However, in 2025, the company's stock price fell by 36.22%, and it is projected to report a net loss of 330 million to 410 million yuan for the year [6]. - Following the announcement of the share reduction plan, Wantai Biological's stock price experienced a slight decline over three consecutive days, closing at 40.47 yuan, with a market capitalization of approximately 51.17 billion yuan. The stock has seen a decline of over 70% from its historical peak [6]. Investor Concerns - Investors have expressed concerns regarding the potential impact of the share reduction on market liquidity, questioned the choice of centralized bidding over block trading, and raised doubts about the complexity of the donation process [7].